Novavax Archives | Page 5 of 6 | Be Korea-savvy
Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate

Novavax Announces Positive Phase 1 Data for its COVID-19 Vaccine Candidate

GAITHERSBURG, Md., Aug. 4 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID‑19 vaccine with and without Matrix‑M™ adjuvant in healthy adults 18-59 years of age. NVX‑CoV2373, the Company’s recombinant [...]

Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate

Novavax and FUJIFILM Diosynth Biotechnologies Initiate Large Scale Manufacturing of COVID-19 Vaccine Candidate

GAITHERSBURG, Md. and MORRISVILLE, N.C., July 23 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and FUJIFILM Diosynth Biotechnologies (FDB), a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today an agreement to manufacture bulk drug substance [...]

Novavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress

Novavax to Present COVID-19 Vaccine Candidate Progress at 2nd ISV COVID-19 Vaccines Virtual Congress

GAITHERSBURG, Md., July 20 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D., President of Research and Development, will present progress of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, at the 2nd International Society for Vaccines Virtual Congress. Dr. Glenn’s presentation will [...]

Novavax Announces $1.6 Billion Funding from Operation Warp Speed

Novavax Announces $1.6 Billion Funding from Operation Warp Speed

GAITHERSBURG, Md., July 7 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has been selected to participate in Operation Warp Speed (OWS), a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for [...]

Novavax Announces Updates to Leadership Team

Novavax Announces Updates to Leadership Team

GAITHERSBURG, Md., July 2 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Frank Czworka as Senior Vice President, Global Sales, with responsibility for leading sales planning and distribution. Novavax also announced the promotion of Brian Webb to Senior Vice President, [...]

Novavax Expands Executive Leadership and Announces Key Promotions

Novavax Expands Executive Leadership and Announces Key Promotions

GAITHERSBURG, Md., June 29 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Ben Machielse as Executive Vice President, CMC, with responsibility for overseeing Novavax’ manufacturing, process technology, quality and regulatory functions. The Company also announced several leadership promotions: John J. Trizzino to [...]

Novavax to Participate in H.C. Wainwright Fireside Chat Series

Novavax to Participate in H.C. Wainwright Fireside Chat Series

GAITHERSBURG, Md., June 24 (Korea Bizwire) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25. A topic [...]

Novavax Announces Additions to Executive Leadership

Novavax Announces Additions to Executive Leadership

GAITHERSBURG, Md., June 17 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of two senior executives to the leadership team. Filip Dubovsky, M.D., MPH, FAAP, has been appointed Senior Vice President and Chief Medical Officer, where he will oversee Novavax’ medical [...]

Novavax Appoints Biotechnology Veteran David Mott to Board of Directors

Novavax Appoints Biotechnology Veteran David Mott to Board of Directors

GAITHERSBURG, Md., June 16 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has appointed David Mott as an independent director to its Board of Directors. Mr. Mott brings more than three decades of global management, board and investment experience across numerous [...]

Novavax to Raise $200 Million from Private Placement with RA Capital

Novavax to Raise $200 Million from Private Placement with RA Capital

GAITHERSBURG, Md., June 15 (Korea Bizwire) — Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has entered into an agreement to sell Series A Convertible preferred stock, convertible into 4,388,852 shares of common stock, to an investment fund affiliated with RA Capital Management (RA [...]